Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Diarmuid O’Brien will take over as chief executive of Cambridge Enterprise this September following the retirement of Tony Raven.
Four of the incubator’s portfolio companies will pitch to investors at the GCV Digital Forum 3.0 following the success of similar competitions at our previous events.
Tony Raven, CEO of Cambridge Enterprise and a GUV Lifetime Achievement awardee, will step down by the end of next year.
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.